AccuBioTech

AccuBioTech Co., Ltd. is a biotechnology company specializing in the development, manufacturing, and distribution of in vitro diagnostic (IVD) rapid tests and analyzers. Founded in 2004 and based in Beijing, China, the company offers a wide range of diagnostic products used globally in hospitals, clinical laboratories, physician offices, and by home users.

Key Product Categories:

Fertility Tests: Products designed to detect fertility-related hormones, aiding in family planning and reproductive health.
Infectious Disease Tests: Rapid tests for the detection of various infectious agents, including hepatitis, HIV, and influenza.
Inflammation Tests: Diagnostic tools to measure markers of inflammation, assisting in the assessment of inflammatory conditions.
Drugs of Abuse Tests: Screening tests for the detection of illicit drug use.
Tumor Markers: Tests that help in the early detection of certain types of cancer.
Cardiac Tests: Diagnostic products for the rapid assessment of cardiac biomarkers, aiding in the diagnosis of acute cardiac events.
Urine Reagent Tests: Tests for the analysis of urine samples, providing insights into various health conditions.

Recent Developments:

Hepatitis Rapid Test Kits: AccuBioTech offers a comprehensive range of hepatitis rapid test kits, including those for HAV, HBsAg, HBsAb, HBeAg, HBeAb, HBcAb, HBV, and HCV, supporting global efforts in hepatitis prevention and control.
Influenza A+B Cassette: In line with WHO recommendations, AccuBioTech provides rapid diagnostic tests for Influenza A and B, enhancing influenza prevention and control measures.
Participation in Medlab Middle East 2025: The company showcased its products and technologies at the Medlab Middle East 2025 Exhibition, receiving positive feedback for its high-sensitivity diagnostic solutions.

Browse AccuBioTech Products

6-MAM Cassette

SKU: ABT-DOA-B166|Size: 25 Tests

6-MAM Strip

SKU: ABT-DOA-A166|Size: 50 Tests

ACE Cassette

SKU: ABT-DOA-B139|Size: 25 Tests

ACE Strip

SKU: ABT-DOA-A139|Size: 50 Tests

AMP Cassette

SKU: ABT-DOA-B24|Size: 25 Tests

AMP Strip

SKU: ABT-DOA-A24|Size: 50 Tests

Adenovirus Cassette

SKU: ABT-IDT-B100|Size: 20 Tests

Adulteration Strip (Urine) - 1 parameter

SKU: ABT-DOA-A382|Size: 50 Tests

Adulteration Strip (Urine) - 2 parameter

SKU: ABT-DOA-A412|Size: 50 Tests

Adulteration Strip (Urine) - 3 parameter

SKU: ABT-DOA-A413|Size: 50 Tests

Adulteration Strip (Urine) - 6 parameter

SKU: ABT-DOA-A335|Size: 50 Tests

Alcohol Strip

SKU: ABT-ACH-A187|Size: 50 Tests

BAR Cassette

SKU: ABT-DOA-B28|Size: 25 Tests

BAR Strip

SKU: ABT-DOA-A28|Size: 50 Tests

BUP Cassette

SKU: ABT-DOA-B140|Size: 25 Tests

BUP Strip

SKU: ABT-DOA-A140|Size: 50 Tests

BZO Cassette

SKU: ABT-DOA-B29|Size: 25 Tests

BZO Strip

SKU: ABT-DOA-A29|Size: 50 Tests

CK-MB Cassette

SKU: ABT-CT-B66|Size: 25 Tests

CMV IgG Cassette

SKU: ABT-FT-B230|Size: 25 Tests

CMV IgG/IgM Cassette

SKU: ABT-FT-B307|Size: 25 Tests

CMV IgM Cassette

SKU: ABT-FT-B211|Size: 25 Tests

COC Cassette

SKU: ABT-DOA-B23|Size: 25 Tests

COC Strip

SKU: ABT-DOA-A23|Size: 50 Tests

COT Cassette

SKU: ABT-DOA-B141|Size: 25 Tests

COT Strip

SKU: ABT-DOA-A141|Size: 50 Tests

COVID-19 Antigen Cassette

SKU: ABT-IDT-B372|Size: 25 Tests

COVID-19 IgG/IgM Cassette

SKU: ABT-IDT-B352|Size: 25 Tests

CRP Semi-Quantitative Cassette (1/3/10 mg/L)

SKU: ABT-CT-B251|Size: 25 Tests

CRP Semi-Quantitative Cassette (10/40/80mg/L)

SKU: ABT-INF-B318|Size: 20 Tests

Calprotectin Semi-Quantitative Cassette

SKU: ABT-INF-B398|Size: 15 Tests

Chagas Cassette

SKU: ABT-IDT-B219|Size: 25 Tests

Chikungunya IgG/IgM Cassette

SKU: ABT-IDT-B220|Size: 25 Tests

Chlamydia Cassette

SKU: ABT-STD-B18|Size: 20 Tests

Clostridium difficile GDH+Toxin A+Toxin B Combo Cassette

SKU: ABT-IDT-B316|Size: 15 Tests

D-Dimer Cassette

SKU: ABT-CT-B110|Size: 25 Tests

Dengue IgG/IgM Cassette

SKU: ABT-IDT-B97|Size: 20 Tests

Dengue IgG/IgM/NS1 Combo Cassette

SKU: ABT-IDT-B217|Size: 20 Tests

Dengue NS1 Antigen Cassette

SKU: ABT-IDT-B216|Size: 20 Tests

EDDP Cassette

SKU: ABT-DOA-B151|Size: 25 Tests

EDDP Strip

SKU: ABT-DOA-A151|Size: 50 Tests

ETG Cassette

SKU: ABT-DOA-B170|Size: 25 Tests

ETG Strip

SKU: ABT-DOA-A170|Size: 50 Tests

FOB Cassette

SKU: ABT-FOB-B22|Size: 20 Tests

FOB Strip

SKU: ABT-FOB-A22|Size: 20 Tests

FOB/TF Cassette

SKU: ABT-TM-B250|Size: 20 Tests

FYL Cassette

SKU: ABT-DOA-B159|Size: 25 Tests

FYL Strip

SKU: ABT-DOA-A159|Size: 50 Tests

GAB Cassette

SKU: ABT-DOA-B432|Size: 25 Tests

GAB Strip

SKU: ABT-DOA-A432|Size: 50 Tests

H. pylori Antigen Cassette

SKU: ABT-IDT-B76|Size: 20 Tests

H. pylori IgG Cassette

SKU: ABT-IDT-B13|Size: 25 Tests

H. pylori IgG/IgM/IgA Cassette

SKU: ABT-IDT-B385|Size: 25 Tests

H. pylori IgG/IgM/IgA Strip

SKU: ABT-IDT-A385|Size: 50 Tests

HAV IgG Cassette

SKU: ABT-IDT-B231|Size: 25 Tests

HAV IgM Cassette

SKU: ABT-IDT-B218|Size: 25 Tests

HAV IgM/IgG Cassette

SKU: ABT-IDT-B226|Size: 25 Tests

HAV-Ab Elisa

SKU: ABT-EIA-F9|Size: 96 Tests

HAV-IgM Elisa

SKU: ABT-EIA-F31|Size: 96 Tests

HBV Cassette

SKU: ABT-IDT-E65|Size: 15 Tests

HBcAb Cassette

SKU: ABT-IDT-B10|Size: 25 Tests

HBcAb Elisa

SKU: ABT-EIA-F5|Size: 96 Tests

HBcAb IgM Elisa

SKU: ABT-EIA-F10|Size: 96 Tests

HBeAb Cassette

SKU: ABT-IDT-B8|Size: 25 Tests

HBeAb Elisa

SKU: ABT-EIA-F3|Size: 96 Tests

HBeAg Cassette

SKU: ABT-IDT-B9|Size: 25 Tests

HBeAg Elisa

SKU: ABT-EIA-F2|Size: 96 Tests

HBsAb Cassette

SKU: ABT-IDT-B7|Size: 25 Tests

HBsAb Elisa

SKU: ABT-EIA-F4|Size: 96 Tests

HBsAb Quantitative Elisa

SKU: ABT-EIA-F32|Size: 96 Tests

HBsAb Strip

SKU: ABT-IDT-A7|Size: 50 Tests

HBsAg Cassette

SKU: ABT-IDT-B5|Size: 25 Tests

HBsAg Elisa

SKU: ABT-EIA-F1|Size: 96 Tests

HBsAg Elisa (High Sensitivity)

SKU: ABT-EIA-F12|Size: 96 Tests

HBsAg Strip

SKU: ABT-IDT-A5|Size: 50 Tests

HBsAg/HCV Combo Cassette

SKU: ABT-IDT-B56|Size: 20 Tests

HBsAg/HCV/HIV Combo Cassette

SKU: ABT-IDT-B233|Size: 20 Tests

HBsAg/HCV/HIV/Syphilis Combo Cassette

SKU: ABT-IDT-B78|Size: 15 Tests

HCG Cassette

SKU: ABT-FT-B1|Size: 25 Tests

HCG Midstream

SKU: ABT-FT-C1|Size: 1 Test

HCG Multi-Line Midstream

SKU: ABT-FT-C387|Size: 1 Test

HCG Multi-Line Strip

SKU: ABT-FT-A387|Size: 50 - 100 Tests

HCG Strip

SKU: ABT-FT-A1|Size: 100 Tests

HCV Cassette

SKU: ABT-IDT-B11|Size: 25 Tests

HCV Elisa

SKU: ABT-EIA-F6|Size: 96 Tests

HCV Elisa (sandwich)

SKU: ABT-EIA-F13|Size: 96 Tests

HCV Strip

SKU: ABT-IDT-A11|Size: 50 Tests

HCV/HIV/Syphilis Combo Cassette

SKU: ABT-IDT-B245|Size: 20 Tests

HIV 1+2 Ag/Ab Elisa

SKU: ABT-EIA-F14|Size: 96 Tests

HIV 1+2 Elisa

SKU: ABT-EIA-F7|Size: 96 Tests

HIV 1.2.O Cassette

SKU: ABT-IDT-B84|Size: 25 Tests

HIV 1.2.O P24 Ab Cassette

SKU: ABT-IDT-B376|Size: 25 Tests

HIV 1/2 Cassette

SKU: ABT-IDT-B14|Size: 25 Tests

HIV 1/2 Strip

SKU: ABT-IDT-A50|Size: 50 Tests

HIV Ag/Ab Combo Cassette

SKU: ABT-IDT-B265|Size: 25 Tests

HSV -2 IgG Cassette

SKU: ABT-FT-B323|Size: 25 Tests

HSV -2 IgG/IgM Cassette

SKU: ABT-FT-B310|Size: 25 Tests

HSV 1/2 IgM Cassette

SKU: ABT-FT-B212|Size: 25 Tests

HbA1c Semi-Quantitative Cassette

SKU: ABT-OTH-B429|Size: 20 Tests

Influenza A+B Cassette

SKU: ABT-IDT-B247|Size: 20 Tests

Recent Breakthroughs

Design, synthesis, and antidiabetic activity of new furan-clubbed 1,2,3-triazole derivatives as <i>α</i>-glucosidase inhibitors.

Devi P, Maity S, Singh A, Mehan S, Singh G, Asati V.

Future Med Chem

PMID:41994872

Free PMC article

Aim The study aims to design, synthesize, and evaluate novel furan-clubbed 1,2,3-triazole derivatives as potential α-glucosidase inhibitors for the management of diabetes mellitus. Materials and methods Ten furan-clubbed-1,2,3-triazole derivatives PD(1-10) were synthesized and characterized through sophisticated instrumentation techniques, including FT-IR, 1 H NMR, 13 C NMR, and LC-MS. The compounds were assessed in vitro for their ability to inhibit the α-glucosidase enzyme. The in vivo antidiabetic effect of the best molecules was evaluated using STZ-nicotinamide induced diabetic mouse model. The observed results were further supported by molecular docking against α-glucosidase (PDB ID: 3L4U) and histopathological examinations. Results The results of in vitro studies showed that the test compound PD-10 exhibited the strongest α-glucosidase inhibition (IC 5 0 = 13.82 μM), outperforming acarbose (IC 5 0 = 32.03 μM), followed by PD-1 and PD-6 . Further, the in vivo antidiabetic evaluation of the best compounds adjudged compound PD-10 as the best molecule among the series. Docking analyses indicated a significant binding affinity of PD-10 (-4.34 kcal/mol). Conclusions The research highlights PD-10 as a promising α-glucosidase inhibitor with strong in vitro and in vivo antidiabetic effects, supported by favorable molecular docking interactions, and emphasizes its potential for development as an antidiabetic lead for further studies and evaluations.

Mechanistic perspectives on antimalarial agents: from FDA-approved drugs to next-generation candidates.

Monika, Sharma B, Awasthi SK.

RSC Adv

PMID:42006802

Free PMC article

Malaria is a major global health challenge, demanding continued innovation in drug discovery and development. This review gives a comprehensive overview of FDA-approved antimalarial drugs and emerging clinical candidates, focusing their chemical structures, mechanisms of action, and molecular targets such as PfATP4, DHFR, DHODH, and PfCRT. The discussion showcases structure-activity relationships, mechanisms underlying drug resistance, and recent advances in structure-guided design of next-generation antimalarials. The review also summarizes the year of approval, mechanistic class, and synthetic origin of key therapeutic agents. Moreover, novel molecules currently in preclinical and clinical trials are discussed in the context of their mode of action, efficacy, and potential for overcoming resistance. Collectively, this article bridges medicinal chemistry insights with biological mechanisms, outlining future directions in the rational design of potent, resistance-resilient antimalarial drugs.

Total chemical synthesis of pentameric cholera toxin subunit B.

Spaltenstein P, Scherer SR, Jones TE, Giesler RJ, Kay MS.

Chem Commun (Camb)

PMID:41891529

Free PMC article

Vibrio cholerae annually infects millions worldwide, causing intense and life-threatening diarrheal disease. The pentameric cholera toxin subunit B (CtxB) binds to the ganglioside GM1 on epithelial cells, initiating endocytosis and downstream toxicity. We present the total chemical protein synthesis of L-CtxB and mirror-image D-CtxB using a three-segment N-to-C native chemical ligation approach. Oxidative folding produced the desired 62 kDa pentameric proteins, with L-CtxB capable of binding native GM1 ligand. Synthetic D-CtxB is now ready to serve as a target in mirror-image phage display, representing a significant milestone for the discovery of toxin-neutralizing D-peptides to treat and prevent cholera.

Can amoxicillin be detected in the aquatic environment? A critical assessment.

Hernández F, Botero-Coy AM, Bijlsma L, Fabregat-Safont D.

Environ Int

PMID:42001666

Free PMC article

Amoxicillin is a broad-spectrum β-lactam antibiotic widely used in both human and veterinary medicine. Following administration, approximately 60-80% of the dose is excreted, largely unmetabolized, via urine within a few hours. Consequently, environmental contamination with amoxicillin, especially in aquatic systems, is a significant concern. Due to its potential ecological risks and the current scarcity of data required for a full assessment, it was included in two consecutive European Union Watch Lists (2018, 2020) of substances for comprehensive monitoring to inform water policy. However, data on amoxicillin levels in aquatic environments are contradictory, ranging from high concentrations in some studies to non-detection in others. The presence of intact amoxicillin in aquatic environments is inherently transient, and the risk of substantial analytical errors in its detection, identification, and quantification is considerable unless stringent methodological precautions are applied. Driven by the need for reliable environmental data, inconsistencies in the existing literature and our own extensive analytical experience, we comprehensively investigated amoxicillin degradation in surface water, influent and effluent wastewater under various conditions. Experiments were conducted under both dark and sunlight conditions using water samples spiked with amoxicillin at 5 μg/L and 50 μg/L. The parent compound was quantified by liquid chromatography-tandem mass spectrometry, whereas transformation products were identified by high-resolution mass spectrometry. By critically assessing the factors that influence the analysis and environmental occurrence of amoxicillin, this study resolves discrepancies in prior reports and clarifies the realistic prospects for its detection. We demonstrate that the parent antibiotic should be rarely found in water samples due to its rapid degradation. Therefore, future monitoring efforts should be focused on its primary degradation product, amoxicillin penicilloic acid, as more reliable indicator of contamination in aquatic environments.

Characterising the urinary metabolome in HIV/TB coinfection and the impact of antiretroviral treatment.

Allen B, Wood R, Luies L.

BMC Infect Dis

PMID:41992151

Free PMC article

Background HIV/TB coinfection poses significant challenges due to complex interactions between both pathogens and the metabolic disruptions they induce. Although antiretroviral treatment (ART) has transformed disease management, its impact on metabolism is not fully understood. Metabolomics offers an in-depth approach to explore the metabolic changes in this coinfected population, providing information into disease mechanisms and the effects of ART. Methods This exploratory study used untargeted urine gas chromatography mass spectrometry metabolomics to profile metabolic alterations in treatment-naïve HIV/TB coinfected patients and those on ART. Healthy controls were included for comparison. Metabolite changes were analysed using univariate statistical methods, including Kruskal-Wallis tests and pairwise comparisons, to identify key metabolites associated with coinfection and ART. Results Findings revealed significant disruptions in several metabolic pathways. Mitochondrial dysfunction was evident, contributing to altered lipid metabolism, impaired energy production, and increased cardiovascular risk. Disruptions in glucose metabolism, including compromised insulin secretion, were observed, alongside evidence of gut dysbiosis linked to inflammation and microbial imbalance. These metabolic disturbances were also associated with increased oxidative stress, reflected in changes to protein metabolism and the development of cachexia. Although ART partially alleviated some metabolic alterations, disruptions remained evident in treated patients. Conclusion This study provides a comprehensive view of the metabolic disturbances in HIV/TB coinfection and the impact of ART. Our findings suggest that persistent mitochondrial dysfunction, altered lipid metabolism, and gut dysbiosis contribute to ongoing metabolic imbalances, underscoring the need for targeted therapeutic strategies to address these challenges.